Using nanosacs to deliver siRNA for treating head and neck cancer
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
This study is looking at a new way to help people with advanced head and neck cancer by using tiny delivery systems to send special RNA directly to the tumor, which could make existing treatments work better and offer a more effective option for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-10770423 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for advanced head and neck squamous cell cancer by using nanosacs to deliver small interfering RNA (siRNA) directly to tumor cells. The approach aims to enhance the effectiveness of checkpoint blockade immunotherapy, which has had limited success with traditional antibody treatments. By developing a safe and effective delivery system for siRNA, the research seeks to overcome barriers that have previously hindered the use of RNA-based therapies in cancer treatment. Patients may benefit from a more effective and targeted treatment option that could potentially improve survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced or metastatic head and neck squamous cell cancer who have limited treatment options.
Not a fit: Patients with early-stage head and neck cancer or those who do not have squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and more effective treatment option for patients with advanced head and neck cancer.
How similar studies have performed: While the use of siRNA in cancer treatment is a promising area, this specific approach using nanosacs for systemic delivery in head and neck cancer is relatively novel and has not been extensively tested.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Yeo, Yoon — Purdue University
- Study coordinator: Yeo, Yoon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.